Skip to main content
VNDA logo

VNDA · Vanda Pharmaceuticals Inc.

$5.16 -0.06 (-1.15%) At close · Jul 28
Market Cap
$313.91M
Shares
60.14M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Mihael Polymeropoulos $3,851,468
Joakim Wijkstrom $1,457,528
Timothy Williams $1,444,969
Kevin Moran $1,439,660
Gunther Birznieks $1,415,471
Fiscal 2024
Executive Total
Mihael Polymeropoulos $3,896,241
Timothy Williams $1,453,114
Kevin Moran $1,447,627
Gunther Birznieks $1,423,438
Joakim Wijkstrom $1,061,306
Fiscal 2023
Executive Total
Mihael Polymeropoulos $3,720,215
Timothy Williams $1,399,802
Gunther Birznieks $1,373,008
Joakim Wijkstrom $1,355,478
Kevin Moran $1,324,684
Fiscal 2022
Executive Total
Mihael Polymeropoulos $4,269,410
Joakim Wijkstrom $1,616,850
Timothy Williams $1,504,866
Gunther Birznieks $1,471,317
Kevin Moran $1,440,701
Fiscal 2021
Executive Total
Mihael Polymeropoulos $6,194,157
Timothy Williams $2,032,128
Gunther Birznieks $2,000,853
Kevin Moran $1,971,966
Joakim Wijkstrom $1,850,376
Fiscal 2020
Executive Total
Mihael Polymeropoulos $2,913,420
Joakim Wijkstrom $1,523,885
Timothy Williams $1,379,061
Gunther Birznieks $1,377,808
Kevin Moran $1,319,699
James P. Kelly $140,274
Fiscal 2019
Executive Total
Mihael Polymeropoulos $4,278,137
Gian Piero Reverberi $2,296,319
James P. Kelly $2,248,410
Timothy Williams $2,022,854
Gunther Birznieks $2,010,821
Fiscal 2018
Executive Total
Mihael Polymeropoulos $4,024,728
James P. Kelly $2,401,385
Gian Piero Reverberi $2,145,907
Timothy Williams $2,002,856
Gunther Birznieks $1,873,006
Fiscal 2017
Executive Total
Mihael Polymeropoulos $6,265,989
James P. Kelly $2,276,307
Gunther Birznieks $2,098,792
Gian Piero Reverberi $1,755,570

Executive changes

Person Change Filed
Charles C. Duncan, Ph.D. Appointed 2026-04-22
Timothy Williams Resigned 2026-04-02
Key facts CIK 1347178 CUSIP 921659108 13F (30d) 26 filings 26 filers Visit website Investor relations